Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | EEF2K | O00418 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19437507 | 0.88 | TLR8 (0.45) | KMT2ACYP1A2CYP2D6STING1TLR8 | |
| SCHEMBL19437550 | 0.85 | TLR8 (0.52) | KMT2ASTING1TLR8JAK2JAK1 | |
| SCHEMBL19437658 | 0.81 | STING1 (0.52) | KMT2ASTING1 | |
| Bromide SCHEMBL19436512 | 0.80 | KMT2A (0.52) | KMT2ASTING1TLR8JAK2JAK1 | |
| SCHEMBL22136271 | 0.78 | TLR7 (0.43) | STING1TLR8 | |
| SCHEMBL19437587 | 0.78 | TLR8 (0.42) | CYP2D6STING1TLR8JAK2JAK1 | |
| SCHEMBL22121411 | 0.77 | KMT2A (0.52) | KMT2APTGER4JAK2JAK1TYK2 | |
| SCHEMBL21643841 | 0.77 | STING1 (0.42) | KMT2ASTING1 | |
| SCHEMBL21643845 | 0.77 | STING1 (0.42) | KMT2ASTING1 | |
| SCHEMBL19437503 | 0.74 | KMT2A (0.74) | KMT2ACYP1A2CYP2D6HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| EP-3440072-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| EP-3440072-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017175156-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | ARGLU1, G3BP1, G3BP2 | KMT2A 2117/4885ACSS2 336/4885CYP1A2 3565/4885 |
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | ARGLU1, G3BP1, G3BP2 | KMT2A 2117/4885ACSS2 336/4885CYP1A2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.